Abstract

APOBEC3G (A3G) is a host cytidine deaminase that, in the absence of Vif, restricts HIV-1 replication and reduces the amount of viral DNA that accumulates in cells. Initial studies determined that A3G induces extensive mutation of nascent HIV-1 cDNA during reverse transcription. It has been proposed that this triggers the degradation of the viral DNA, but there is now mounting evidence that this mechanism may not be correct. Here, we use a natural endogenous reverse transcriptase assay to show that, in cell-free virus particles, A3G is able to inhibit HIV-1 cDNA accumulation not only in the absence of hypermutation but also without the apparent need for any target cell factors. We find that although reverse transcription initiates in the presence of A3G, elongation of the cDNA product is impeded. These data support the model that A3G reduces HIV-1 cDNA levels by inhibiting synthesis rather than by inducing degradation.

Highlights

  • APOBEC3G (A3G) is a potent anti-viral polynucleotide cytidine deaminase, initially identified as the cellular target of the HIV-1 viral infectivity factor (Vif) protein [1]

  • We have analyzed the effects of APOBEC3G, a potent HIV-1 inhibitor, on viral reverse transcription using cell-free viruses

  • We report that APOBEC3G inhibits viral DNA synthesis in a dose-dependent fashion, and does not require editing capabilities to do so

Read more

Summary

Introduction

APOBEC3G (A3G) is a potent anti-viral polynucleotide cytidine deaminase, initially identified as the cellular target of the HIV-1 viral infectivity factor (Vif) protein [1]. Since this discovery, many APOBEC proteins from various species have been shown to inhibit the replication of a diverse range of viruses and retrotransposons (see [2,3,4] for reviews). The second observed phenotype is a reduction in the accumulation of viral cDNA in target cells [11,13,14,15,16,17,18,19,20] This could occur either by triggering degradation of reverse transcripts or by inhibiting DNA synthesis

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call